Invasive candidiasis management, simplified with once-weekly REZZAYO™
Indication
REZZAYO™ (rezafungin for injection) is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data.1
Patients with invasive candidiasis or candidemia tend to be critically ill and may be on other therapies, such as broad-spectrum antibiotics, corticosteroids, immunosuppressants, or anticancer medications. The choice of antifungal can further complicate these factors.1-4
When you start REZZAYO™1
No clinically relevant drug-
drug interactions
No dose adjustments for
special populations
No requirement for a PICC or
central line
No impact on QTc interval
Can be used in patients with
renal impairment
Administer in a variety of
care settings
PICC=peripherally inserted central catheter; QTc=corrected QT interval.
The first echinocandin in more than 15 years1,5
The once-weekly dosing schedule of REZZAYO™ may help simplify treatment logistics1,2
Allows patients to avoid an invasive PICC but still benefit from echinocandin treatment
May help facilitate continuity of echinocandin treatment and reduce unnecessary switching or discontinuation of life-saving medication as the patient moves to lower-intensity care or outpatient treatment
Could save time and staff resources associated with daily infusions related to management of invasive candidiasis
Has the potential to reduce the number of healthcare touchpoints for patients needing echinocandin treatment
Offers patients who cannot take oral medications a once-weekly option6
Adherence is of the utmost importance for life-saving medications. The once-weekly HCP-administered dose of REZZAYO™ may provide greater transparency into patient adherence7
